6TVG image
Entry Detail
PDB ID:
6TVG
Keywords:
Title:
Human CD73 (ecto 5'-nucleotidase) in complex with AMPCP in the open state
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-01-09
Release Date:
2020-02-26
Method Details:
Experimental Method:
Resolution:
1.48 Å
R-Value Free:
0.16
R-Value Work:
0.12
R-Value Observed:
0.12
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:5'-nucleotidase, ecto (CD73), isoform CRA_a
Chain IDs:A
Chain Length:546
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
2-Substituted alpha , beta-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
J.Med.Chem. 63 2941 2957 (2020)
PMID: 32045236 DOI: 10.1021/acs.jmedchem.9b01611

Abstact

CD73 inhibitors are promising drugs for the (immuno)therapy of cancer. Here, we present the synthesis, structure-activity relationships, and cocrystal structures of novel derivatives of the competitive CD73 inhibitor α,β-methylene-ADP (AOPCP) substituted in the 2-position. Small polar or lipophilic residues increased potency, 2-iodo- and 2-chloro-adenosine-5'-O-[(phosphonomethyl)phosphonic acid] (15, 16) being the most potent inhibitors with Ki values toward human CD73 of 3-6 nM. Subject to the size and nature of the 2-substituent, variable binding modes were observed by X-ray crystallography. Depending on the binding mode, large species differences were found, e.g., 2-piperazinyl-AOPCP (21) was >12-fold less potent against rat CD73 compared to human CD73. This study shows that high CD73 inhibitory potency can be achieved by simply introducing a small substituent into the 2-position of AOPCP without the necessity of additional bulky N6-substituents. Moreover, it provides valuable insights into the binding modes of competitive CD73 inhibitors, representing an excellent basis for drug development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures